FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism

The drug is the first approved in 12 years to treat secondary hyperparathyroidism in hemodialysis patients, and the first that can be given intravenously by a dialysis team.FDA Approvals

Source: Medscape Pharmacist Headlines - February 8, 2017 Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news